| |
Thursday, February 27, 2025 I 12 PM ET See top clinical investigators, medical & trial experts share their game-changing insights to optimize dose escalation, patient recruitment and safety oversight. Register now.
|
|
Today’s Big NewsFeb 19, 2025 |
|
| Wednesday, February 26, 2025 | 12pm ET / 9am PTIn today’s world, life sciences and healthcare companies face major challenges — managing complex datasets, accelerating drug discovery, and advancing precision research. Register for our webinar to learn how to overcome these challenges using AI cloud infrastructure and advanced machine learning tools. |
|
| By James Waldron Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret antigens that could form the backbone of off-the-shelf immunotherapies. |
|
|
|
By Gabrielle Masson Cabaletta’s new data slice for its investigational CD19-CAR T cell therapy shows “robust benefit” for patients with lupus and dermatomyositis without the need for steroids or immunosuppressants, according to William Blair analysts. |
By Nick Paul Taylor Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. The Chinese biotech ticked the publication of multiple ascending dose data off its to-do list Wednesday, linking its oral GLP-1 prospect to 6.3% mean body weight loss after 28 days. |
Sponsored by Grifols Nearly one million people in the U.S. and more than six million people worldwide have Parkinson's disease (PD), a debilitating neurological condition characterized by progressive motor and non-motor symptoms that significantly affects patients and their loved ones. |
By Gabrielle Masson While the FDA’s diversity guidance for clinical trials has been temporarily restored, the page its housed on now carries a message from the Trump administration that the guidance “does not reflect biological reality.” |
By Darren Incorvaia After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged fraudulent claims by the drug’s original maker. The Danish pharma giant plans to seek $830 million in damages from Singapore-based KBP Biosciences and KBP’s founder and executive chairman, Zhenhua Huang, Ph.D. |
By Darren Incorvaia Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset missed its primary endpoint in a phase 2b trial. SPN-820 failed to improve the symptoms of patients with treatment-resistant depression after four weeks, the company announced on Feb. 18. |
By Nick Paul Taylor Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying China’s CSPC Megalith Biopharmaceutical $15 million upfront for rights to an antibody-drug conjugate, securing itself a shot at challenging Merck & Co. for the opportunity. |
By James Waldron Recce Pharmaceuticals’ synthetic anti-infective gel successfully treated a range of skin infections in a mid-stage test, setting the Australian biotech’s sights on a registrational phase 3 trial. |
By Conor Hale It’s unclear how many staff at the FDA have been affected. There have also been estimates of thousands of dismissals spanning the NIH, the CDC and other agencies across the HHS. |
By Angus Liu After Novartis and Roche grew their sales last year, the Swiss pharma giants are handing their CEOs larger compensation packages for 2024. |
By Dave Muoio The White House's latest executive order would give the president greater control over federal agencies typically shielded by cross-term leadership appointments and dismissal protections. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we celebrate Valentine's Day with a discussion about heart-related updates and the stories we've loved covering so far this year. |
|
|---|
|
|
| Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
